Looking at Humira's original BLA filed in 2002 (12

Looking at Humira's original BLA filed in 2002 (125057) and then it has 53 Supplemental labels attached to this same BLA (125057). I did not look at the labels to differentiate, but this is how I thought the leronlimab would file their BLAs (original BLA for combo and then all other leronlimab indications would be supplemental filings). I know the clinical trials would all be independent, but IMO supplemental labels would be easier, less paperwork as the non-clinical and CMC portions would be largely the same, cheaper, and faster approval.

I am missing something or do you agree?

https://www.accessdata.fda.gov/scripts/cder/d...lNo=125057

Please do your own due diligence. All my posts and comments are not to be considered investment advice.